Navigation Links
Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
Date:9/23/2010

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biosimilar immune biologics will erode $10.8 billion in immune biologics brand sales in 2019 alone across the U.S., EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan. According to Biosimilars Advisory Service: Physician Perspectives on Pegylated Interferon-alpha and TNF-alpha Inhibitors in Immune and Infectious Disease, competition between branded and biosimilar TNF-alpha inhibitors and pressure to reduce costs through biosimilars use will contribute to a substantial erosion of brand sales.

Biosimilars' anticipated lower costs compared with branded biologics will be a major driver of their use among both U.S. and European gastroenterologists and rheumatologists. The majority of surveyed U.S. physicians in these specialties say that a policy that reduces or eliminates out-of-pocket costs for patients would significantly or moderately increase their prescribing of biosimilars. In France and Germany, where the cost burden on patients with serious disease is minimal, surveyed gastroenterologists and rheumatologists indicate biosimilars' potential to lower costs to their institutions and clinics will be a key driver of biosimilar use.

"While sales and costs associated with immune biologics, and TNF-alpha inhibitors in particular, make these agents an attractive target for manufacturers and payers, the extent to which biosimilars are able to reduce costs may be limited because of two main factors," said Decision Resources Analyst MaryEllen Klusacek, Ph.D. "First, high development and manufacturing costs for TNF-alpha inhibitors will likely prevent biosimilars in this class from being as steeply discounted as generic small molecule therapies. Second, our primary research suggests that gastroenterologists and rheumatologists will exhibit fairly conservative attitudes toward biosimilar uptake."

The Physician Perspectives on Pegylated Interferon-alpha and TNF-alpha Inhibitors in Immune and Infectious Disease module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German gastroenterologists and rheumatologists to highlight the key expectations that will drive or constrain biosimilar adoption.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision ResourcesDecision Resources, Inc.Lisa Osgood

Christopher Comfort781-993-2606

781-993-2597 losgood@dresources.com   ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Peptimmune Presentations at Upcoming Events
9. Protein-printing technique gives snapshots of immune system defense
10. Visualizing asthma-causing immune cells at work
11. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has ... has hosted corporate cooking challenges for companies around the world, such as Illumina, HP and ... of the reason for its increasing popularity is due to its new team building format, ...
(Date:3/23/2017)... March 23, 2017  GlobeImmune, Inc. today announced it ... sale of 12,835,490 shares of its common stock to ... companies. In connection with the sale of its common stock, ... and issue to GlobeImmune 200,000 shares, an estimated $2.0 ... "We are pleased to enter into this strategic ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ... strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 ...
Breaking Biology Technology:
(Date:2/27/2017)... Feb. 27, 2017   Strategic Cyber Ventures , ... has led a $3.5 million investment in  Polarity , ... Cyber Ventures is DC based and is led by ... Thomas . Ron Gula , also a longtime ... participated in this series A round of funding. This ...
(Date:2/24/2017)... Spain , Feb. 24, 2017  EyeLock LLC, a ... demonstrate its elite iris biometric solution on the ... X16 LTE at Mobile World Congress 2017 ... Qualcomm,s Booth in Hall 3, Stand 3E10. ... the Qualcomm Haven™ security platform—a combination of ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
Breaking Biology News(10 mins):